Cargando…
Androgen Deprivation Induces Transcriptional Reprogramming in Prostate Cancer Cells to Develop Stem Cell-Like Characteristics
Enzalutamide, an antiandrogen, is approved for therapy of castration resistant prostate cancer. Clinical applications have shown that approximately 30% of patients acquire resistance after a short period of treatment. However, the molecular mechanisms underlying this resistance is not completely und...
Autores principales: | Verma, Shiv, Shankar, Eswar, Kalayci, F. Naz Cemre, Mukunda, Amrita, Alassfar, Malek, Singh, Vaibhav, Chan, E. Ricky, MacLennan, Gregory T., Gupta, Sanjay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7765584/ https://www.ncbi.nlm.nih.gov/pubmed/33339129 http://dx.doi.org/10.3390/ijms21249568 |
Ejemplares similares
-
Increased cytokine gene expression and cognition risk associated with androgen deprivation therapy
por: Verma, Shiv, et al.
Publicado: (2022) -
Metabolic Reprogramming and Predominance of Solute Carrier Genes during Acquired Enzalutamide Resistance in Prostate Cancer
por: Verma, Shiv, et al.
Publicado: (2020) -
Identification of Key Genes Associated with Progression and Prognosis of Bladder Cancer through Integrated Bioinformatics Analysis
por: Verma, Shiv, et al.
Publicado: (2021) -
Suppression of NF-κB and NF-κB-Regulated Gene Expression by Apigenin through IκBα and IKK Pathway in TRAMP Mice
por: Shukla, Sanjeev, et al.
Publicado: (2015) -
Androgen Deprivation Induces Reprogramming of Prostate Cancer Cells to Stem-Like Cells
por: Sánchez, Belén G., et al.
Publicado: (2020)